Ashland INC 8-K filings

Ashland Inc. has amended its Receivables Purchase Agreement, extending the facility's termination date to July 28, 2028, and maintaining commitments at $70 million.

Ashland Inc. announced the appointment of two new independent directors and the formation of a Capital Allocation Advisory Committee as part of a cooperation agreement with stockholder Ancora Holdings Group, LLC.

Ashland Inc. announced preliminary third quarter 2026 results, showing a seven percent increase in sales to $497 million, while reaffirming its full-year sales and Adjusted EBITDA guidance.

Ashland Inc. has entered into a new five-year, $500 million revolving credit facility to support ongoing working capital and general corporate purposes, replacing its previous agreement.

Ashland Inc. announced the appointment of Bertrand Loy as an independent director to its Board, effective May 15, 2026, increasing the board size to nine members.

Ashland reports Q2 2026 sales of $482 million and updates full-year guidance due to operational challenges at its Hopewell facility.

Ashland Inc. reported a 5% sales decline to $386 million in Q1 fiscal 2026, narrowing its full-year Adjusted EBITDA guidance due to temporary operational impacts.

Ashland Inc. awarded its CEO, Guillermo Novo, a one-time $2 million equity grant in restricted stock units to ensure his continued leadership through at least December 31, 2028.

Ashland Inc. announced the results of its annual stockholders' meeting, where all director nominees were elected, Ernst & Young LLP was ratified as auditor, and executive compensation was approved.

Ashland Inc. announced preliminary fourth quarter and fiscal year 2025 results, along with its fiscal year 2026 outlook, reflecting disciplined performance amidst challenging market conditions.

Ashland Inc. announced the resignation of Sergio Pedreiro from its Board of Directors, effective September 30, 2025, reducing the board size to eight members.

Ashland Inc. announced a significant third-quarter net loss of $742 million, primarily due to a $706 million non-cash goodwill impairment charge, and revised its full-year fiscal 2025 financial guidance to a narrower, more cautious range.

Ashland Inc. filed an amended 8-K to correct the vesting date of Performance Share Units granted to its Senior Vice President Chief Financial Officer, William Whitaker, from November 20, 2029, to November 20, 2028.

Ashland Inc. has officially appointed William Whitaker as its Senior Vice President, Chief Financial Officer, and Principal Financial Officer, solidifying his interim role and detailing his compensation package.

Ashland Inc. announced the retirement of Senior Vice President of Operations Karl Bostaph, effective October 1, 2025, with Wayne Muil appointed as his successor to ensure a seamless transition.

Ashland Inc. reports the resignation of its CFO, J. Kevin Willis, and the appointment of William C. Whitaker as Interim CFO, along with the appointment of Samuel A. Richardson as Principal Accounting Officer.

Ashland Inc. announced its second quarter fiscal year 2025 results, reporting sales of $479 million and revising its full-year outlook due to a weakening macroeconomic environment.

Ashland Inc. announced its first quarter fiscal year 2025 financial results, reporting sales of $405 million and reiterating its full-year fiscal 2025 outlook.

Ashland Inc. appoints J. Kevin Willis as Principal Accounting Officer and successfully conducts its annual meeting with key proposals approved by stockholders.

Ashland Inc. has announced that Eric F. Boni, Vice President, Finance and Principal Accounting Officer, will depart from the company following a brief transition period.

Ashland Inc. announced its fourth-quarter fiscal 2024 results, showing a slight sales increase but with adjusted EBITDA below expectations, and issued its outlook for fiscal year 2025.

Ashland Inc. announces that board member Wetteny Joseph will not seek reelection at the 2025 Annual Meeting of Stockholders.

Ashland Inc. has amended its Receivables Purchase Agreement, reducing the maximum facility size and extending the termination date.

Ashland Inc. announced its third quarter fiscal 2024 results, showing a slight sales decrease but an increase in adjusted EBITDA, while also issuing a cautious outlook for the fourth quarter and full year.

Ashland Inc. has appointed Ashish K. Kulkarni, CEO of Kebotix, to its Board of Directors, effective May 6, 2024.

Ashland Inc. has signed a definitive agreement to sell its nutraceuticals business to Turnspire Capital Partners, anticipating a non-cash impairment charge in the range of $110 million to $120 million.

Ashland Inc. announced its second quarter fiscal 2024 results, showing a sales decrease but increased net income, and provided an improved outlook for the full fiscal year.

Ashland Inc. reports the resignation of Ashok Kalyana, Senior Vice President and General Manager, Life Sciences and Intermediates, effective May 10, 2024.

Ashland Inc. has appointed Scott A. Tozier, a former executive of Albemarle Corporation, to its Board of Directors, effective April 15, 2024.

Ashland Inc. reports that Senior Vice President and General Manager, Min Chong, will depart from the company on April 30, 2024, triggering severance benefits.